Maria G. Esteve-Comas

Terrassa, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 155 publications

Position statement of the spanish working group on crohn's disease and ulcerative colitis (geteccu) on the diagnosis and management of acute severe ulcerative colitis.

Position statement of the spanish working group on crohn's disease and ulcerative colitis (geteccu) on the diagnosis and management of acute severe ulcerative colitis.

Journal: Gastroenterologia y hepatologia

Published: May 05, 2026

Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the diagnosis and management of acute severe ulcerative colitis.

Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the diagnosis and management of acute severe ulcerative colitis.

Journal: Gastroenterologia y hepatologia

Published: May 05, 2026

Non-celiac gluten sensitivity: balance between hype and hard reality.

Non-celiac gluten sensitivity: balance between hype and hard reality.

Journal: Medicina clinica

Published: January 31, 2026

Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry.

Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry.

Journal: United European gastroenterology journal

Published: October 23, 2025

Rationale and design of the NATURCEL registry: Study of the NATURal history and the epidemiological, clinical, diagnostic and therapeutic aspects of CoELiac disease and noncoeliac enteropathies.

Rationale and design of the NATURCEL registry: Study of the NATURal history and the epidemiological, clinical, diagnostic and therapeutic aspects of CoELiac disease and noncoeliac enteropathies.

Journal: Gastroenterologia y hepatologia

Published: October 16, 2025

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.

Journal: Journal of Crohn's & colitis

Published: October 09, 2025

TL1A-activated T cells remodel the rectal mucosa in patients with Crohn's disease with perianal fistulising disease.

TL1A-activated T cells remodel the rectal mucosa in patients with Crohn's disease with perianal fistulising disease.

Journal: Gut

Published: June 30, 2025

Coeliac Disease, Microscopic Colitis, and Exclusion Diets-A Commemorative Issue in Honor of Dr. Fernando Fernández-Bañares.

Coeliac Disease, Microscopic Colitis, and Exclusion Diets-A Commemorative Issue in Honor of Dr. Fernando Fernández-Bañares.

Journal: Nutrients

Published: April 15, 2025

Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics.

Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics.

Journal: Frontiers in cellular and infection microbiology

Published: March 18, 2025

Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA.

Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA.

Journal: Alimentary pharmacology & therapeutics

Published: March 03, 2025

ICD-10-CM coding uncovers the gap between serological and clinically identified coeliac disease prevalence: A population-based study.

ICD-10-CM coding uncovers the gap between serological and clinically identified coeliac disease prevalence: A population-based study.

Journal: European journal of internal medicine

Published: February 21, 2025

Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.

Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.

Journal: Alimentary pharmacology & therapeutics

Published: January 14, 2025

Showing 1-12 of 155

Last Updated: 09/26/2026